JP2016509591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016509591A5 JP2016509591A5 JP2015550788A JP2015550788A JP2016509591A5 JP 2016509591 A5 JP2016509591 A5 JP 2016509591A5 JP 2015550788 A JP2015550788 A JP 2015550788A JP 2015550788 A JP2015550788 A JP 2015550788A JP 2016509591 A5 JP2016509591 A5 JP 2016509591A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- diastereomer
- compound
- enantiomer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 168
- 150000001875 compounds Chemical class 0.000 claims description 133
- 150000003839 salts Chemical class 0.000 claims description 116
- 229910052739 hydrogen Inorganic materials 0.000 claims description 88
- 239000001257 hydrogen Substances 0.000 claims description 76
- 150000002431 hydrogen Chemical class 0.000 claims description 72
- -1 OR 9 Chemical group 0.000 claims description 63
- 125000004429 atom Chemical group 0.000 claims description 48
- 239000012453 solvate Substances 0.000 claims description 47
- 229940002612 prodrug Drugs 0.000 claims description 42
- 239000000651 prodrug Substances 0.000 claims description 42
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 40
- 229910052736 halogen Inorganic materials 0.000 claims description 40
- 150000002367 halogens Chemical class 0.000 claims description 40
- 125000000623 heterocyclic group Chemical group 0.000 claims description 40
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 36
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 34
- 125000001072 heteroaryl group Chemical group 0.000 claims description 26
- 125000003107 substituted aryl group Chemical group 0.000 claims description 25
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 18
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 17
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 15
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 10
- 125000004122 cyclic group Chemical group 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 10
- 125000001246 bromo group Chemical group Br* 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 125000002837 carbocyclic group Chemical group 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 230000019552 anatomical structure morphogenesis Effects 0.000 claims description 4
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 208000002672 hepatitis B Diseases 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 125000006384 methylpyridyl group Chemical group 0.000 claims description 4
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- JNHULJPDNUCLHD-UHFFFAOYSA-N 5-[[3-[(4-methoxyphenyl)carbamoyl]phenyl]sulfonylamino]pentanoic acid Chemical compound C1=CC(OC)=CC=C1NC(=O)C1=CC=CC(S(=O)(=O)NCCCCC(O)=O)=C1 JNHULJPDNUCLHD-UHFFFAOYSA-N 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 150000004703 alkoxides Chemical class 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 150000001409 amidines Chemical class 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 125000004342 dicyclopropylmethyl group Chemical group [H]C1([H])C([H])([H])C1([H])C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- FVMAYATYZSYSFZ-UHFFFAOYSA-N n-(3-methoxy-5-phenoxypyridin-2-yl)-3-pyrrolidin-1-ylsulfonylbenzamide Chemical compound C=1N=C(NC(=O)C=2C=C(C=CC=2)S(=O)(=O)N2CCCC2)C(OC)=CC=1OC1=CC=CC=C1 FVMAYATYZSYSFZ-UHFFFAOYSA-N 0.000 claims description 2
- WFLQINZNNVGHIX-UHFFFAOYSA-N n-(3-methoxy-5-phenylsulfanylpyridin-2-yl)-3-pyrrolidin-1-ylsulfonylbenzamide Chemical compound C=1N=C(NC(=O)C=2C=C(C=CC=2)S(=O)(=O)N2CCCC2)C(OC)=CC=1SC1=CC=CC=C1 WFLQINZNNVGHIX-UHFFFAOYSA-N 0.000 claims description 2
- NPZTXJPMHHMWHQ-UHFFFAOYSA-N n-(5-bromo-3-methoxypyridin-2-yl)-3-piperidin-1-ylsulfonylbenzamide Chemical compound COC1=CC(Br)=CN=C1NC(=O)C1=CC=CC(S(=O)(=O)N2CCCCC2)=C1 NPZTXJPMHHMWHQ-UHFFFAOYSA-N 0.000 claims description 2
- SEFGEXQGNGLZAG-UHFFFAOYSA-N n-(5-ethenyl-3-methoxypyridin-2-yl)-3-piperidin-1-ylsulfonylbenzamide Chemical compound COC1=CC(C=C)=CN=C1NC(=O)C1=CC=CC(S(=O)(=O)N2CCCCC2)=C1 SEFGEXQGNGLZAG-UHFFFAOYSA-N 0.000 claims description 2
- MAQWAGCJOFDDNU-UHFFFAOYSA-N n-(5-ethyl-3-methoxypyridin-2-yl)-3-piperidin-1-ylsulfonylbenzamide Chemical compound COC1=CC(CC)=CN=C1NC(=O)C1=CC=CC(S(=O)(=O)N2CCCCC2)=C1 MAQWAGCJOFDDNU-UHFFFAOYSA-N 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 150000004885 piperazines Chemical class 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 45
- 239000002904 solvent Substances 0.000 claims 24
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 4
- 150000004677 hydrates Chemical class 0.000 claims 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 150000001728 carbonyl compounds Chemical class 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 0 CC1=CCCC(C2(*)CC2)=C1 Chemical compound CC1=CCCC(C2(*)CC2)=C1 0.000 description 32
- 125000000753 cycloalkyl group Chemical group 0.000 description 15
- 238000000034 method Methods 0.000 description 5
- DQOGDQIDOONUSK-REOHCLBHSA-N C[C@H](C(F)(F)F)C(O)=O Chemical compound C[C@H](C(F)(F)F)C(O)=O DQOGDQIDOONUSK-REOHCLBHSA-N 0.000 description 4
- DQOGDQIDOONUSK-UWTATZPHSA-N C[C@@H](C(F)(F)F)C(O)=O Chemical compound C[C@@H](C(F)(F)F)C(O)=O DQOGDQIDOONUSK-UWTATZPHSA-N 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- FILOYPQPSRQLRL-NRFANRHFSA-N 3-piperidin-1-ylsulfonyl-n-[(1s)-1,2,3,4-tetrahydronaphthalen-1-yl]benzamide Chemical compound N([C@@H]1C2=CC=CC=C2CCC1)C(=O)C(C=1)=CC=CC=1S(=O)(=O)N1CCCCC1 FILOYPQPSRQLRL-NRFANRHFSA-N 0.000 description 1
- BGNWXRJWDQHCRB-UHFFFAOYSA-N CC(C)c1ncccn1 Chemical compound CC(C)c1ncccn1 BGNWXRJWDQHCRB-UHFFFAOYSA-N 0.000 description 1
- WPPZHQBTLCZSEY-UHFFFAOYSA-N CC1(C)N=CC=C(C)N1 Chemical compound CC1(C)N=CC=C(C)N1 WPPZHQBTLCZSEY-UHFFFAOYSA-N 0.000 description 1
- ZHUGZTZOGHQIOD-UHFFFAOYSA-N CC1(C)OC(C)=NC=C1 Chemical compound CC1(C)OC(C)=NC=C1 ZHUGZTZOGHQIOD-UHFFFAOYSA-N 0.000 description 1
- LRNKDEJJYFZZOV-SCSAIBSYSA-N C[C@@H](C(F)(F)F)C(OC1(CC1)C(O)=O)=O Chemical compound C[C@@H](C(F)(F)F)C(OC1(CC1)C(O)=O)=O LRNKDEJJYFZZOV-SCSAIBSYSA-N 0.000 description 1
- FZMPLKVGINKUJZ-UHFFFAOYSA-N Cc(cc1F)ccc1F Chemical compound Cc(cc1F)ccc1F FZMPLKVGINKUJZ-UHFFFAOYSA-N 0.000 description 1
- BPWJEVHPHKDCLD-UHFFFAOYSA-N O=C(c(cc1)cc(F)c1F)NC(CC1S(NC2CC2)(=O)=O)=CC=C1F Chemical compound O=C(c(cc1)cc(F)c1F)NC(CC1S(NC2CC2)(=O)=O)=CC=C1F BPWJEVHPHKDCLD-UHFFFAOYSA-N 0.000 description 1
- FABZZCLPYQXJEY-UHFFFAOYSA-N O=C(c(cc1)cc(F)c1F)Nc(cc1NS(C2CC2)(=O)=O)ccc1F Chemical compound O=C(c(cc1)cc(F)c1F)Nc(cc1NS(C2CC2)(=O)=O)ccc1F FABZZCLPYQXJEY-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261746552P | 2012-12-27 | 2012-12-27 | |
| US61/746,552 | 2012-12-27 | ||
| PCT/US2013/077940 WO2014106019A2 (en) | 2012-12-27 | 2013-12-27 | Novel antiviral agents against hbv infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018177094A Division JP2019034943A (ja) | 2012-12-27 | 2018-09-21 | Ｈｂｖ感染に対する新規抗ウイルス剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016509591A JP2016509591A (ja) | 2016-03-31 |
| JP2016509591A5 true JP2016509591A5 (enExample) | 2016-07-21 |
| JP6409001B2 JP6409001B2 (ja) | 2018-10-17 |
Family
ID=51022201
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015550788A Expired - Fee Related JP6409001B2 (ja) | 2012-12-27 | 2013-12-27 | Ｈｂｖ感染に対する新規抗ウイルス剤 |
| JP2018177094A Pending JP2019034943A (ja) | 2012-12-27 | 2018-09-21 | Ｈｂｖ感染に対する新規抗ウイルス剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018177094A Pending JP2019034943A (ja) | 2012-12-27 | 2018-09-21 | Ｈｂｖ感染に対する新規抗ウイルス剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9938236B2 (enExample) |
| EP (1) | EP2938338A4 (enExample) |
| JP (2) | JP6409001B2 (enExample) |
| KR (1) | KR101942151B1 (enExample) |
| CN (1) | CN105209031A (enExample) |
| AU (2) | AU2013370300B2 (enExample) |
| BR (1) | BR112015015584A2 (enExample) |
| CA (1) | CA2896554C (enExample) |
| EA (1) | EA201591220A1 (enExample) |
| HK (1) | HK1217649A1 (enExample) |
| IL (2) | IL239397B (enExample) |
| MX (1) | MX2015008471A (enExample) |
| PH (1) | PH12015501473A1 (enExample) |
| SG (2) | SG10201803698UA (enExample) |
| WO (1) | WO2014106019A2 (enExample) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX359634B (es) | 2011-12-21 | 2018-10-03 | Novira Therapeutics Inc | Agentes antivirales contra la hepatitis b. |
| EP2890688A1 (en) * | 2012-08-28 | 2015-07-08 | Janssen Sciences Ireland UC | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| CN105209031A (zh) * | 2012-12-27 | 2015-12-30 | 德雷克塞尔大学 | 针对hbv感染的新型抗病毒剂 |
| WO2014131847A1 (en) | 2013-02-28 | 2014-09-04 | Janssen R&D Ireland | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| EA027068B1 (ru) | 2013-04-03 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| HUE039152T2 (hu) | 2013-07-25 | 2018-12-28 | Janssen Sciences Ireland Uc | Glioxamiddal szubsztituált pirrolamid-származékok és alkalmazásuk hepatitisz B kezelésére szolgáló gyógyszerként |
| JP6452119B2 (ja) | 2013-10-23 | 2019-01-16 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用 |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| CA2936947A1 (en) | 2014-02-05 | 2015-08-13 | Novira Therapeutics, Inc. | Combination therapy for treatment of hbv infections |
| WO2015118057A1 (en) | 2014-02-06 | 2015-08-13 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| EP3607950A3 (en) | 2014-03-13 | 2020-03-18 | Indiana University Research & Technology Corporation | Hepatitis b core protein allosteric modulators |
| US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
| US20170266197A1 (en) * | 2014-05-09 | 2017-09-21 | Indiana University Research And Technology Corporation | Methods and compositions for treating hepatitis b virus infections |
| CA2969557A1 (en) * | 2014-12-02 | 2016-06-09 | Novira Therapeutics, Inc. | Sulfide alkyl and pyridyl reverse sulfonamide compounds for hbv treatment |
| US9597332B2 (en) | 2014-12-02 | 2017-03-21 | Novira Therapeutics, Inc. | Sulfide alkyl compounds for HBV treatment |
| MA41140A (fr) * | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| US9765050B2 (en) | 2014-12-30 | 2017-09-19 | Novira Therapeutics, Inc. | Pyridyl reverse sulfonamides for HBV treatment |
| WO2016107832A1 (en) | 2014-12-30 | 2016-07-07 | F. Hoffmann-La Roche Ag | Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection |
| US9884831B2 (en) | 2015-03-19 | 2018-02-06 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
| WO2016161268A1 (en) | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
| EP3292120B1 (en) * | 2015-05-04 | 2019-06-19 | H. Hoffnabb-La Roche Ag | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections |
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| WO2017011552A1 (en) | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| TWI721016B (zh) | 2015-09-15 | 2021-03-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| US10077239B2 (en) | 2015-09-29 | 2018-09-18 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
| CA3017020C (en) | 2016-03-07 | 2024-01-16 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| AU2017248828A1 (en) * | 2016-04-15 | 2018-11-01 | Janssen Sciences Ireland Uc | Combinations and methods comprising a capsid assembly inhibitor |
| US11124490B2 (en) * | 2016-06-03 | 2021-09-21 | University Of Tennessee Research Foundation | Autotaxin inhibitors |
| AU2017277664A1 (en) | 2016-06-10 | 2019-01-24 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| MA45999A (fr) | 2016-08-22 | 2019-06-26 | Arbutus Biopharma Corp | Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CA3036245C (en) | 2016-09-13 | 2021-07-20 | Arbutus Biopharma Corporation | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same |
| AU2017326356A1 (en) | 2016-09-15 | 2019-04-11 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
| WO2018085619A1 (en) | 2016-11-07 | 2018-05-11 | Arbutus Biopharma, Inc. | Substituted pyridinone-containing tricyclic compounds, and methods using same |
| EA037576B1 (ru) * | 2016-11-11 | 2021-04-15 | Новира Терапьютикс, Инк. | Комбинации и способы, включающие ингибитор сборки капсида |
| CN110300579A (zh) * | 2017-02-07 | 2019-10-01 | 詹森药业有限公司 | 氨磺酰基芳基衍生物及其作为药物用于治疗肝纤维化的用途 |
| RU2650610C1 (ru) | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Противовирусная композиция и способ ее применения |
| US11078170B2 (en) | 2017-03-02 | 2021-08-03 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
| WO2018172852A1 (en) | 2017-03-21 | 2018-09-27 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
| JP7377718B2 (ja) | 2017-05-12 | 2023-11-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | アポトーシスシグナル調節キナーゼ１阻害剤およびその使用方法 |
| WO2019001420A1 (en) | 2017-06-27 | 2019-01-03 | Janssen Pharmaceutica Nv | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING INFECTIONS WITH HEPATITIS B VIRUS |
| US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| AU2018326474B2 (en) | 2017-08-28 | 2024-07-25 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2019046186A1 (en) | 2017-08-28 | 2019-03-07 | Enanta Pharmaceuticals, Inc. | INHIBITORS OF KINASE 1 REGULATING THE APOPTOTIC SIGNAL CONTAINING TETRAZOLES AND METHODS OF USE THEREOF |
| TW201912153A (zh) * | 2017-08-30 | 2019-04-01 | 加拿大商愛彼特生物製藥公司 | 用於治療ｂ型肝炎的化合物、醫藥組合物及方法 |
| US10428070B2 (en) | 2017-12-06 | 2019-10-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10723733B2 (en) | 2017-12-06 | 2020-07-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| JP2021515769A (ja) | 2018-03-14 | 2021-06-24 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カプシド集合調節剤の投薬レジメン |
| WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2019206072A1 (zh) * | 2018-04-24 | 2019-10-31 | 浙江海正药业股份有限公司 | 磺酰胺芳基甲酰胺衍生物及其制备方法和用途 |
| WO2019213239A1 (en) * | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| AU2019262016B2 (en) | 2018-05-02 | 2024-07-11 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| EP3597637A1 (en) | 2018-07-19 | 2020-01-22 | Irbm S.P.A. | Inhibitors of hepatitis b virus |
| EP3597653A1 (en) | 2018-07-19 | 2020-01-22 | Irbm S.P.A. | Cyclic inhibitors of hepatitis b virus |
| EP3830093A1 (en) | 2018-07-27 | 2021-06-09 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
| TWI826492B (zh) | 2018-07-27 | 2023-12-21 | 加拿大商愛彼特生物製藥公司 | 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法 |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| EP3608326A1 (en) | 2018-08-10 | 2020-02-12 | Irbm S.P.A. | Tricyclic inhibitors of hepatitis b virus |
| US10968199B2 (en) | 2018-08-22 | 2021-04-06 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| TW202024093A (zh) | 2018-09-21 | 2020-07-01 | 美商安塔製藥公司 | 作為抗病毒劑之官能化雜環 |
| BR112021006403A2 (pt) * | 2018-10-05 | 2021-07-06 | Univ Emory | agentes monômeros e multiméricos anti-hbv |
| US11560370B1 (en) | 2018-10-22 | 2023-01-24 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of HBV |
| US20210395751A1 (en) | 2018-10-31 | 2021-12-23 | The University Of Sydney | Compositions and methods for treating viral infections |
| WO2020106707A1 (en) | 2018-11-19 | 2020-05-28 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| EP3883570A4 (en) | 2018-11-21 | 2022-07-13 | Enanta Pharmaceuticals, Inc. | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS |
| TWI827760B (zh) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
| US11952330B2 (en) | 2019-02-05 | 2024-04-09 | Board Of Regents, The University Of Texas System | Antibiotic ammonium compounds and methods for the treatment of bacterial infections |
| AU2020223865A1 (en) | 2019-02-22 | 2021-07-15 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| US11466033B2 (en) | 2019-03-25 | 2022-10-11 | Enanta Pharmaceuticals, Inc. | Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors |
| TW202108576A (zh) | 2019-05-06 | 2021-03-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之醯胺衍生物 |
| EP3741762A1 (en) | 2019-05-23 | 2020-11-25 | Irbm S.P.A. | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus |
| UY38705A (es) | 2019-05-23 | 2020-12-31 | Irbm S P A | Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b |
| EP3825318A1 (en) | 2019-11-25 | 2021-05-26 | Promidis S.r.l. | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus |
| JP2022532935A (ja) | 2019-05-24 | 2022-07-20 | アッセンブリー バイオサイエンシズ，インコーポレイテッド | Ｈｂｖの処置のための医薬組成物 |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020255013A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| AU2020352552A1 (en) | 2019-09-23 | 2022-03-17 | Omega Therapeutics, Inc. | Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression |
| JP2022548320A (ja) | 2019-09-23 | 2022-11-17 | オメガ セラピューティクス， インコーポレイテッド | アポリポタンパク質ｂ（ａｐｏｂ）遺伝子発現をモジュレートするための組成物および方法 |
| CN114846051A (zh) | 2019-12-20 | 2022-08-02 | 阿布特斯生物制药公司 | 合成方法和中间体 |
| EP4118207A1 (en) | 2020-03-11 | 2023-01-18 | Omega Therapeutics, Inc. | Compositions and methods for modulating forkhead box p3 (foxp3) gene expression |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| KR20210126507A (ko) | 2020-04-10 | 2021-10-20 | 주식회사 스탠다임 | 벤즈아미드 화합물을 포함하는 암 예방 또는 치료용 조성물 |
| CN111393391B (zh) * | 2020-04-16 | 2022-07-26 | 南京安纳康生物科技有限公司 | 用于乙型肝炎病毒感染的抗病毒剂 |
| CN111349056B (zh) * | 2020-04-16 | 2022-08-02 | 南京安纳康生物科技有限公司 | 用于乙型肝炎病毒感染的抗病毒剂 |
| WO2021216660A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2021216642A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | Pyrazole carboxamide compounds for treatment of hbv |
| AU2021261307A1 (en) | 2020-04-22 | 2022-11-17 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of HBV |
| WO2021216661A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | Pyrazole carboxamide compounds for treatment of hbv |
| WO2021222150A2 (en) | 2020-04-28 | 2021-11-04 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| WO2022103899A1 (en) * | 2020-11-10 | 2022-05-19 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2023283359A2 (en) | 2021-07-07 | 2023-01-12 | Omega Therapeutics, Inc. | Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression |
| WO2023069547A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2023069544A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2023069545A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| KR102617049B1 (ko) | 2021-12-30 | 2023-12-21 | 장고옥 | 헤어고데기 |
| WO2023164179A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
| WO2023164186A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
| WO2023164181A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
| WO2023164183A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
| CR20240391A (es) | 2022-03-23 | 2024-11-05 | Ideaya Biosciences Inc | Compuestos de indazol sustituidos con piperazina como inhibidores de parg |
| JPWO2024029481A1 (enExample) * | 2022-08-01 | 2024-02-08 | ||
| JP2025529185A (ja) * | 2022-08-30 | 2025-09-04 | パンネックス セラピューティクス インコーポレイテッド | パネキシン－１調節剤及びパネキシン－１が関与する疾患の治療方法 |
| CN115677545B (zh) * | 2022-10-28 | 2024-03-15 | 潍坊医学院 | 一种抗hbv磺胺苯甲酰胺类衍生物及其制备方法和应用 |
| CN116410106B (zh) * | 2023-04-13 | 2024-12-06 | 山东第二医科大学 | 一种苯甲酰胺类hbv衣壳蛋白抑制剂及其制备方法与应用 |
| WO2024243438A2 (en) | 2023-05-23 | 2024-11-28 | Omega Therapeutics, Inc. | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression |
| WO2025043094A1 (en) | 2023-08-23 | 2025-02-27 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2891938A (en) * | 1957-03-29 | 1959-06-23 | Geigy Ag J R | Chromium-containing monoazo dyestuffs |
| US3557111A (en) * | 1968-03-29 | 1971-01-19 | Bola Vithal Shetty | N and n,n-alkyl,acyl and arylsulfamyl-tetrahydroquinazolinones |
| US3567746A (en) * | 1968-07-10 | 1971-03-02 | Pennwalt Corp | N-aryl benzamides |
| JPH0625106B2 (ja) | 1985-07-24 | 1994-04-06 | 三共株式会社 | イソインドリン−１，３−ジオン誘導体およびその製造法 |
| JP2000212157A (ja) * | 1999-01-13 | 2000-08-02 | Warner Lambert Co | ジアリ―ルアミン |
| IL144144A0 (en) | 1999-01-13 | 2002-05-23 | Bayer Ag | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| BR9916885A (pt) * | 1999-01-13 | 2001-11-20 | Warner Lambert Co | Derivados de benzeno-sulfonamida e seu uso comoinibidores da mek |
| WO2007056016A2 (en) * | 2005-11-02 | 2007-05-18 | Kemia, Inc. | Bisamide cytokine inhibitors |
| JP2009518442A (ja) * | 2005-12-05 | 2009-05-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性エポキシド加水分解酵素インヒビターとして有益な置換ピラゾール化合物 |
| US7842713B2 (en) | 2006-04-20 | 2010-11-30 | Pfizer Inc | Fused phenyl amido heterocyclic compounds |
| EP2099300A4 (en) * | 2006-12-05 | 2011-12-07 | Glaxosmithkline Llc | IL-8 RECEPTOR ANTAGONISTS |
| JP2008184403A (ja) * | 2007-01-29 | 2008-08-14 | Japan Health Science Foundation | 新規ｃ型肝炎ウイルス阻害剤 |
| WO2008137794A1 (en) * | 2007-05-04 | 2008-11-13 | Irm Llc | Compounds and compositions as c-kit and pdgfr kinase inhibitors |
| PH12012502343A1 (en) * | 2007-05-23 | 2013-06-17 | Siga Tech Inc | Antiviral drugs for treatment or prevention of dengue infection |
| JP2010535172A (ja) | 2007-08-02 | 2010-11-18 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｎｓ障害の処置のためのベンズアミド誘導体の使用 |
| DE102007041116A1 (de) * | 2007-08-30 | 2009-03-05 | Merck Patent Gmbh | 1,3-Dihydro-isoindolderivate |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US20090197787A1 (en) | 2008-02-04 | 2009-08-06 | Eurotab | Multilayer Detergent Tablet |
| TW200946526A (en) | 2008-02-06 | 2009-11-16 | Glaxo Group Ltd | Dual pharmacophores-PDE4-muscarinic antagonistics |
| US8263642B2 (en) | 2008-06-25 | 2012-09-11 | Vanderbilt University | Antimicrobial compounds and methods of use thereof |
| EP2236505A1 (de) * | 2009-04-03 | 2010-10-06 | Bayer CropScience AG | Acylierte Aminopyridine und - pyridazine als Insektizide |
| WO2010123139A1 (ja) * | 2009-04-24 | 2010-10-28 | 持田製薬株式会社 | スルファモイル基を有するアリールカルボキサミド誘導体 |
| EP3078377A3 (en) * | 2009-05-12 | 2017-04-05 | Romark Laboratories, L.C. | Nitazoxanide and tizoxanide as anti-viral agents |
| WO2011088561A1 (en) | 2010-01-20 | 2011-07-28 | University Of Manitoba | Anti-viral compounds and compositions |
| US9115127B2 (en) * | 2010-08-05 | 2015-08-25 | Amgen Inc. | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase |
| US8987307B2 (en) | 2011-03-03 | 2015-03-24 | Hoffmann-La Roche Inc. | 3-amino-pyridines as GPBAR1 agonists |
| EP2683244B1 (en) * | 2011-03-08 | 2017-02-01 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
| US9399619B2 (en) * | 2011-07-01 | 2016-07-26 | Baruch S. Blumberg Institute | Sulfamoylbenzamide derivatives as antiviral agents against HBV infection |
| MX359634B (es) | 2011-12-21 | 2018-10-03 | Novira Therapeutics Inc | Agentes antivirales contra la hepatitis b. |
| EP2819671A4 (en) | 2012-02-29 | 2016-05-11 | Baruch S Blumberg Inst | INHIBITORS OF HEPATITIS B VIRUS WITH COVALENT CLOSED CIRCULAR DNA PREPARATION AND ITS USE METHOD |
| EP2890688A1 (en) * | 2012-08-28 | 2015-07-08 | Janssen Sciences Ireland UC | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| JP6353460B2 (ja) * | 2012-12-06 | 2018-07-04 | バルーク エス．ブランバーグ インスティチュート | Ｈｂｖ感染に対する抗ウイルス剤としての官能化ベンズアミド誘導体 |
| CN105209031A (zh) * | 2012-12-27 | 2015-12-30 | 德雷克塞尔大学 | 针对hbv感染的新型抗病毒剂 |
-
2013
- 2013-12-27 CN CN201380072796.5A patent/CN105209031A/zh active Pending
- 2013-12-27 EP EP13868405.5A patent/EP2938338A4/en not_active Withdrawn
- 2013-12-27 MX MX2015008471A patent/MX2015008471A/es unknown
- 2013-12-27 EA EA201591220A patent/EA201591220A1/ru unknown
- 2013-12-27 WO PCT/US2013/077940 patent/WO2014106019A2/en not_active Ceased
- 2013-12-27 BR BR112015015584A patent/BR112015015584A2/pt not_active Application Discontinuation
- 2013-12-27 CA CA2896554A patent/CA2896554C/en not_active Expired - Fee Related
- 2013-12-27 JP JP2015550788A patent/JP6409001B2/ja not_active Expired - Fee Related
- 2013-12-27 KR KR1020157020432A patent/KR101942151B1/ko not_active Expired - Fee Related
- 2013-12-27 AU AU2013370300A patent/AU2013370300B2/en not_active Ceased
- 2013-12-27 HK HK16105705.7A patent/HK1217649A1/zh unknown
- 2013-12-27 SG SG10201803698UA patent/SG10201803698UA/en unknown
- 2013-12-27 SG SG11201504740UA patent/SG11201504740UA/en unknown
- 2013-12-27 US US14/759,385 patent/US9938236B2/en not_active Expired - Fee Related
-
2015
- 2015-06-14 IL IL239397A patent/IL239397B/en not_active IP Right Cessation
- 2015-06-26 PH PH12015501473A patent/PH12015501473A1/en unknown
-
2018
- 2018-03-11 IL IL258007A patent/IL258007A/en unknown
- 2018-03-22 US US15/933,098 patent/US20180230092A1/en not_active Abandoned
- 2018-09-21 JP JP2018177094A patent/JP2019034943A/ja active Pending
-
2019
- 2019-01-31 AU AU2019200663A patent/AU2019200663A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016509591A5 (enExample) | ||
| JP2019034943A5 (enExample) | ||
| RU2419626C2 (ru) | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы | |
| JP2013545798A5 (enExample) | ||
| JP2015509110A5 (enExample) | ||
| JP2020522520A5 (enExample) | ||
| JP2018504393A5 (enExample) | ||
| JP2012524111A5 (enExample) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| JP2005523922A5 (enExample) | ||
| JP2017537940A5 (enExample) | ||
| RU2218337C2 (ru) | Производные тиазола, способ их получения и фармацевтическая композиция на их основе | |
| JP2010520893A5 (enExample) | ||
| JP2007517846A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2008510828A5 (enExample) | ||
| JP2015535252A5 (enExample) | ||
| JPWO2019013311A5 (enExample) | ||
| JP2004502670A5 (enExample) | ||
| JP2013542267A5 (enExample) | ||
| JP2016529235A5 (enExample) | ||
| JP2010527985A5 (enExample) | ||
| RU2015104962A (ru) | Ди- и тригетероарильные производные в качестве ингибиторов агрегации белков | |
| JP2018503661A5 (enExample) | ||
| JP2013506674A5 (enExample) |